http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106459011-A8
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D451-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 |
| filingDate | 2015-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106459011-A8 |
| titleOfInvention | As the receptors ligand drug conjugates of σ 2, its preparation method and use of antitumoral compounds |
| abstract | Disclose the method and composition for treating the cancer such as cancer of pancreas and synovial sarcoma.Describe the compound comprising σ -2 receptor binding moieties and iron death inducing moiety.At least one described molecular substance represents the IC less than 5 μM for human pancreatic cancer cell in vitro 50 Value.Promote pancreatic tumour to shrink in vivo in mouse model system using this material, and cause the 100% of experimental animal to survive in certain time-histories, and in the time-histories, control therapy only provides 30% or 40% survival rate.Also disclose the synthetic method of molecular substance. |
| priorityDate | 2014-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.